Aardvark Therapeutics (NASDAQ:AARD) Stock Gets Price Target Cut from HC Wainwright

Aardvark Therapeutics (NASDAQ:AARD) had its price target reduced by HC Wainwright from $4.00 to $2.00 in a report published on Monday, MarketBeat Ratings reports. They currently have a neutral rating on the stock. HC Wainwright also issued estimates for Aardvark Therapeutics’ Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.40) EPS, Q4 2027 earnings at ($0.43) EPS and FY2027 earnings at ($1.70) EPS.

A number of other equities research analysts have also commented on AARD. BTIG Research dropped coverage on Aardvark Therapeutics in a research report on Monday, October 12th. They issued a “neutral” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Aardvark Therapeutics in a research note on Tuesday, September 29th. Wall Street Zen upgraded Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. UBS Group set a $4.00 price objective on Aardvark Therapeutics in a research note on Monday, October 19th. Finally, Royal Bank Of Canada set a $2.50 price objective on Aardvark Therapeutics in a research note on Friday, October 23rd. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $11.56.

Aardvark Therapeutics Stock Up 16.2%

Shares of Aardvark Therapeutics stock opened at $1.51 on Monday. Aardvark Therapeutics has a twelve month low of $0.93 and a twelve month high of $16.60. The stock has a market cap of $33.04 million, a price-to-earnings ratio of -0.47 and a beta of 3.80. The company’s fifty day moving average is $4.97 and its 200 day moving average is $6.55.

Aardvark Therapeutics (NASDAQ:AARD) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.21. As a group, equities analysts anticipate that Aardvark Therapeutics will post -3.05 earnings per share for the current fiscal year.

Insider Transactions at Aardvark Therapeutics

In related news, insider Nelson Sun sold 62,000 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $5.18, for a total value of $321,160.00. Following the transaction, the insider owned 35,475 shares in the company, valued at $183,760.50. The trade was a 63.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 17.80% of the stock is currently owned by insiders.

Institutional Trading of Aardvark Therapeutics

A number of large investors have recently bought and sold shares of the business. Susquehanna International Group LLP bought a new position in shares of Aardvark Therapeutics in the 2nd quarter worth about $138,000. Bank of New York Mellon Corp boosted its position in shares of Aardvark Therapeutics by 30.8% during the 1st quarter. Bank of New York Mellon Corp now owns 29,320 shares of the company’s stock valued at $111,000 after purchasing an additional 6,905 shares in the last quarter. Ieq Capital LLC bought a new stake in shares of Aardvark Therapeutics during the 2nd quarter valued at about $221,000. J. Goldman & Co LP bought a new stake in shares of Aardvark Therapeutics during the 2nd quarter valued at about $233,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Aardvark Therapeutics during the 1st quarter valued at about $267,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic diseases and other conditions involving appetite regulation. The company’s approach is based on activating bitter taste receptors in the gastrointestinal tract to stimulate the release of gut hormones associated with satiety and metabolic control.

Aardvark’s lead investigational product, ARD-101, is an orally administered, broad-spectrum bitter taste receptor agonist.